{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007692","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.842538+00:00","generated_at":"2026-06-02T03:09:19.945292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Protalix Q1 net loss $4.6M; PRX-115 phase I positive, adds cohort","bullets":["Revenue from goods $3.7M (-27% YoY); license/R&D services $0.1M (-98%) as Elfabrio obligations completed.","Net loss $4.6M ($0.06/shr) vs $3.1M loss ($0.05) YoY; cash $48.5M at quarter end.","PRX-115 phase I: dose-dependent uric acid reduction, well-tolerated; expanding to 8th cohort, planning phase II.","R&D expenses down 50% to $2.9M on completion of Fabry program and Elfabrio regulatory filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007692","json":"https://secwatch.observer/filing/0001558370-24-007692.json","markdown":"https://secwatch.observer/filing/0001558370-24-007692.md","text":"https://secwatch.observer/filing/0001558370-24-007692.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024007692/0001558370-24-007692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024007692/plx-20240510x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:09:19.945292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba0c2a98cff75eddc2a889319e1f5c0bf7f94733","claim":"Protalix BioTherapeutics, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024007692/0001558370-24-007692-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}